Vinpocetine Drugs Market

Sky Rocketing Growth in Vinpocetine Drugs Market by 2027


Vinpocetine (ethyl apovincaminate) is a synthetic derivative of the vinca alkaloid vincamine derived from the seeds of Voacanga africana or the leaves of Vinca minor also known as winkles. For more than three decades, vinpocetine has been clinically indicated for the treatment of cerebrovascular disorders such as stroke and dementia in Europe. Consumers' perceptions of cognitive health have constantly changed in recent years. Market players operating in the nutraceutical industry are looking beyond their immediate counterparts and product categories as new trends emerge.

Request for Sample Copy of this report



Some of the key players of Vinpocetine Drugs Market:

Gedeon Richter, Runhong, Sun Pharma, Wuhan Hualong Biopharmaceutical, Haerbin Medisan, Welman, ZhiTong, Liaoning Zhiying, Micro Labs, Northeast Pharma

Vinpocetine has been clinically indicated in Europe for the treatment of cerebrovascular disorders such as stroke and dementia for more than three decades. Use during pregnancy may harm the baby or lead to miscarriage.

Vinpocetine is not approved for any therapeutic use in the United States. The FDA has ruled that vinpocetine, due to its synthetic nature and proposed therapeutic uses, cannot be marketed as a dietary supplement under the Federal Food, Drug, and Cosmetic Act. Despite this, vinpocetine remains widely available in dietary supplements often marketed as nootropics. The sale of vinpocetine as a supplement is banned in Australia, New Zealand and Canada due to "potentially harmful nootropic characteristics". The evidence does not fully support a benefit in dementia or stroke. In 2003, three controlled clinical trials tested "elderly people with memory problems".

Comments

Popular posts from this blog

Latest Innovation Knocking-in Luxuries Industry

Urgent Care Centers Market

Future Scope for Deep Sea Exploration Robot Industry